StockNews.AI
REPL
StockNews.AI
15 days

Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd

1. Replimune faces a class action lawsuit for securities fraud. 2. The FDA rejected Replimune's Biologics License Application for RP1. 3. Market reaction saw REPL's stock drop 77.24% after negative FDA news. 4. Trial results were deemed inadequate due to patient heterogeneity. 5. Investors can join the lawsuit until September 22, 2025.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The significant stock drop of 77.24% indicates severe investor loss confidence. Past similar situations, like Valeant Pharmaceuticals, showcased long recovery times post litigation.

How important is it?

The lawsuit and FDA rejection critically undermine Replimune's future revenue prospects and investor confidence.

Why Short Term?

The immediate backlash from the FDA response and litigation matters typically affect stock prices swiftly. However, outcomes may improve if the company can provide more compelling data in future trials.

Related Companies

VRTXBMYMAKO
, /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed on behalf of all persons or entities who purchased the securities of Replimune Group, Inc. (NASDAQ: REPL) ("Replimune" or the "Company") PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Class Action Details: Case Filed: A class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) alleging possible securities fraud or other unlawful business practices by the company and certain officers/directors.  Jurisdiction: United States District Court for the District of Massachusetts Class Period: November 22, 2024 – July 21, 2025 Lead Plaintiff Deadline: Investors who bought Replimune shares during the relevant period have until September 22, 2025 to ask the Court to appoint them as Lead Plaintiff. Trigger Event: On July 22, 2025, the FDA issued a Complete Response Letter (CRL) rejecting Replimune's Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) combined with nivolumab to treat advanced melanoma. The FDA found that the IGNYTE trial did not provide adequate or well-controlled clinical evidence of effectiveness. The trial's results were deemed uninterpretable due to patient heterogeneity, and the confirmatory study design needs revisions. No safety concerns were raised. Market Reaction: Following this news, Replimune's stock plummeted by 77.24%, dropping $9.52 to close at $2.81 per share on the same day. Why Wolf Haldenstein Adler Freeman & Herz LLP?: This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors. We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP. Contact: Phone: (800) 575-0735 or (212) 545-4774 Email: [email protected] Contact Person: Gregory Stone, Director of Case and Financial Analysis Firm Website: Wolf Haldenstein Adler Freeman & Herz LLP This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. SOURCE Wolf Haldenstein Adler Freeman & Herz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In Also from this source

Related News